RHABDOMYOSARCOMA

This study tests a personalized treatment plan for children with a rare muscle cancer called rhabdomyosarcoma. Depending on their risk level, they receive a combination of focused proton beam radiation, surgery, and standard or stronger chemotherapy. Intermediate and high-risk pa…

This early-stage study tests whether a treatment made from a patient's own tumor-fighting immune cells (TIL) is safe for children, teenagers, and young adults with solid tumors that have come back or stopped responding to standard treatments. About 40 participants will receive th…

This early-phase study tests a new treatment for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein c…

This study tests a daily pill called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. The drug works by blocking signals that help tumors grow and form blood vessel…

This study tests a more precise way to deliver radiation therapy to children and young adults with bone and soft tissue tumors. By using CT, MRI, and PET scans to map the tumor exactly, doctors can target the cancer while protecting healthy tissue. The goal is to improve tumor co…

This study tests four different chemotherapy schedules for children and teens newly diagnosed with a rare, aggressive muscle cancer (fusion-positive rhabdomyosarcoma) that has already spread. Participants choose one of four approaches: a single intense round, intense round follow…

This early-stage study tests a flavored, drinkable chemotherapy called VAL-413 (Orotecan) for children and young adults (ages 1-30) whose solid tumors have come back. The drug is given by mouth along with another chemo, temozolomide, for 5 days. The main goal is to find the safes…

This early-phase study tests an experimental drug called CLR 131 in children, adolescents, and young adults (ages up to 30) with certain cancers that have come back or not responded to standard treatments. The cancers include solid tumors (like neuroblastoma and sarcomas), lympho…

This study tests whether adding the drug temsirolimus to standard chemotherapy helps children and young adults with intermediate-risk rhabdomyosarcoma, a rare muscle cancer. About 325 participants receive either chemo alone or chemo plus temsirolimus. The goal is to see if the co…

This early-phase study tests a new treatment called CATCH T cells for people with certain solid tumors (like liver cancer) that have come back or not responded to standard care. The treatment involves taking a patient's own immune cells, adding special genes to help them recogniz…

This study tests a new drug called PEN-866 combined with two standard chemotherapy drugs (vincristine and temozolomide) for adolescents and young adults aged 12-39 whose solid tumors, including Ewing sarcoma and rhabdomyosarcoma, have come back or not responded to standard treatm…

This early-stage trial tests a new treatment called AGAR T cells for children whose solid tumors (like liver cancer or rhabdomyosarcoma) have returned or not responded to standard care. The treatment involves taking a patient's own immune cells, adding genes to help them recogniz…

This early-phase study tests a personalized cell therapy for children and young adults (ages 1–30) whose solid tumors have come back or not responded to standard treatment. Researchers take a patient's own immune T cells, modify them to recognize and attack cancer cells that carr…

This study tests two immunotherapy drugs, cobolimab and dostarlimab, together in children and young adults (up to age 21) with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The …

This study looks at whether a special PET scan using a natural amino acid called methionine can help doctors see tumors in children and young adults with cancer. About 500 participants will get the scan to check if it can find tumors at diagnosis and tell the difference between a…

This study tests whether special MRI scans can measure oxygen levels (hypoxia) in childhood sarcomas (soft tissue cancers). The goal is to see if these scans can better show how the tumor responds to chemotherapy or radiation. 18 children and teens aged 6-18 with suspected sarcom…